TSS
VBIO

Two Sigma Securities’s Valion Bio VBIO Stock Holding History

Two Sigma Securities’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,678
Closed -$7.12K – 3145
2024
Q3 		$7.12K Buy
+1,678
New +$10.1K ﹤0.01% 2646
2023
Q3 		– Sell
-57
Closed -$10.3K – 3476
2023
Q2 		$10.3K Buy
+57
New +$12.2K ﹤0.01% 2591
2023
Q1 		– Sell
-7
Closed -$8.05K – 3265
2022
Q4 		$8.05K Buy
+7
New +$15.7K ﹤0.01% 2395

Other funds holding VBIO

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Securities's VBIO Position: Q4 2024 in Review

Two Sigma Securities sold out of Valion Bio (VBIO) in Q4 2024, closing a stake of 1,678 shares — an estimated $7.12K sold.

Two Sigma Securities first reported a position in VBIO in Q4 2022 and held it in 3 quarters. The position peaked at $10.3K in Q2 2023. 9 funds tracked by Wall St. Rank hold VBIO as of Q4 2024.

  • Two Sigma Securities reported no remaining Valion Bio position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Securities sold 1,678 Valion Bio shares in Q4 2024, an estimated $7.12K.
  • Two Sigma Securities first reported a position in Valion Bio in Q4 2022 and held it in 3 quarters.
  • Two Sigma Securities's Valion Bio position peaked at $10.3K in Q2 2023.
  • 9 funds tracked by Wall St. Rank held Valion Bio as of Q4 2024.

Based on Two Sigma Securities's 13F filing for Q4 2024, filed 14 Feb 2025.